NCT07126431
Prospective Cohort Study on Refractory Rheumatoid Arthritis
Recruiting · Not specified · Peking University Third Hospital · registry updated 2026-04-02
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic erosive arthritis. Without timely and appropriate treatment, it can lead to joint destruction and disability. Current RA management emphasizes early diagnosis, early treatment, and a treat-to-target (T2T) approach to achieve disease remission as soon as possible. In recent years, significant progress has been made in RA pharmacotherapy. With the clinical application of biologic disease-modifying antirheumatic drugs (bDMARDs) targeting cytokines and targeted synthetic DMARDs (tsDMARDs), treatment outcomes and prognosis have greatly improved. However, even with bDMARDs or tsDMARDs, some patients show poor response, maintaining moderate-to-high disease activity-a condition termed "refractory RA". Refractory RA has garnered increasing clinical attention, prompting the European Alliance of Associations for Rheumatology (EULAR) to establish a standardized definition and diagnostic criteria in 2020 to facilitate research. Currently, effective treatments for refractory RA are lacking....
Inclusion
- Meet the 1987 American College of Rheumatology (ACR) classification criteria for RA or the 2010 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria for RA.
- Age \>18 years.
- Treatment with conventional synthetic DMARDs (csDMARDs) for at least 1 year.
- Fulfill the EULAR definition of difficult-to-treat RA (refractory RA).
- Provide written informed consent.
Exclusion
- Age \<18 years.
- Duration of DMARD therapy \<1 year.
- Patients unwilling to participate in the cohort study.